Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis

IL-23-induced macrophage polarization and its pathological roles in mice with imiquimod-induced psoriasis

(2018) Yuzhu Hou et al.   Protein & Cell

Psoriasis pathogenesis and the development of novel targeted immune therapies

(2017) Jason E. Hawkes et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

JAK inhibitors in dermatology: The promise of a new drug class

(2017) William Damsky et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

(2017) Dafna Gladman et al.   NEW ENGLAND JOURNAL OF MEDICINE

SOCS3 inhibits the pathological effects of IL-22 in non-melanoma skin tumor-derived keratinocytes

(2017) Stefania Madonna et al.   Oncotarget

Janus kinase inhibitors for rheumatoid arthritis

(2016) Kunihiro Yamaoka   CURRENT OPINION IN CHEMICAL BIOLOGY

Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study

(2016) James Krueger et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis

(2016) Vito Di Lernia et al.   Drug Design Development and Therapy

JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases

(2016) Ana Karina Alves de Medeiros et al.   PLoS One

Activation of the Aryl Hydrocarbon Receptor Dampens the Severity of Inflammatory Skin Conditions

(2014) Paola Di Meglio et al.   IMMUNITY

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis

(2013) W.C. Ports et al.   BRITISH JOURNAL OF DERMATOLOGY

Therapeutical potential of a peptide mimicking the SOCS1 kinase inhibitory region in skin immune responses

(2013) Stefania Madonna et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Suppression of Cytokine Signaling by SOCS3: Characterization of the Mode of Inhibition and the Basis of Its Specificity

(2012) Jeffrey J. Babon et al.   IMMUNITY

A Single Intradermal Injection of IFN-γ Induces an Inflammatory State in Both Non-Lesional Psoriatic and Healthy Skin

(2012) Leanne M. Johnson-Huang et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Anti-apoptotic effects of suppressor of cytokine signaling 3 and 1 in psoriasis

(2012) S Madonna et al.   Cell Death & Disease

Inhibitory effects of the JAK inhibitor CP690,550 on human CD4+ T lymphocyte cytokine production

(2011) Kiyoshi Migita et al.   BMC IMMUNOLOGY

The Multitasking Organ: Recent Insights into Skin Immune Function

(2011) Paola Di Meglio et al.   IMMUNITY

IL-22 Is Required for Imiquimod-Induced Psoriasiform Skin Inflammation in Mice

(2011) A. B. Van Belle et al.   JOURNAL OF IMMUNOLOGY

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

(2011) Kamran Ghoreschi et al.   JOURNAL OF IMMUNOLOGY

Pathobiology of Chronic Inflammatory Skin Diseases: Interplay Between Keratinocytes and Immune Cells as a Target for Anti-Inflammatory Drugs

(2010) C. Albanesi et al.   CURRENT DRUG METABOLISM

STAT3-dependent effects of IL-22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation

(2010) Rosanna Sestito et al.   FASEB JOURNAL

Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling

(2009) Stefanie Eyerich et al.   JOURNAL OF CLINICAL INVESTIGATION

Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis

(2009) L. van der Fits et al.   JOURNAL OF IMMUNOLOGY

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Suppressor of cytokine signaling 1 inhibits IFN-γ inflammatory signaling in human keratinocytes by sustaining ERK1/2 activation

(2008) Stefania Madonna et al.   FASEB JOURNAL